Current Report Filing (8-k)
09 September 2019 - 10:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
September
9, 2019
INTEC
PHARMA LTD.
(Exact
name of registrant as specified in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
12
Hartom St.
Har
Hotzvim
|
|
|
Jerusalem, Israel
|
|
9777512
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
|
+
972-2-586-4657
|
(Registrant’s
telephone number, including area code)
|
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange
on which registered
|
Ordinary
Shares, no, par value
|
|
NTEC
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01. Regulation FD Disclosure.
On
September 9, 2019, Intec Pharma Ltd. (the “Company”) updated its corporate presentation that it intends to use in
conferences and meetings with investors from time to time. The corporate presentation has also been posted on the Company’s
investor relations website at https://ir.intecpharma.com/. A copy of the corporate presentation is being furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein solely for purposes of this Item 7.01 disclosure.
The
furnishing of the corporate presentation is not an admission as to the materiality of any information therein. The information
contained in the corporate presentation is summary information that is intended to be considered in the context of more complete
information included in the Company’s filings with the SEC and other public announcements that the Company has made and
may make from time to time by press release or otherwise. All information contained in the corporate presentation is subject to
the disclaimer regarding forward-looking statements at the beginning of the presentation.
The
information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general
incorporation language in any such filing, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statement and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
September 9, 2019
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/
Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial
Officer
|
2
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2024 to May 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Intec Parent Inc (NASDAQ): 0 recent articles
More Intec Pharma Ltd. News Articles